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Background and Objective
Setting and Methods
Main Outcome Measures
Cure and discontinuation of treatment in a 
tuberculosis control state programme in Brazil: 
insights from dispensing data
Results
• Only site A had an acceptable discontinuation rate, 
in light of the World Health Organization 
recommendations.
• Pharmacists could use dispensing data to signal 
TB patients at-risk of discontinuation, and 
subsequently tailor interventions addressing its 
causes
• Site B had the greater number of patients which 
discontinued treatment. Patients co-infected with 
TB and HIV are firstly referred to this site, which 
may explain this finding.
• Our findings suggest the need of more intensive 
interventions in patients co-infected with TB and 
HIV, such as pharmaceutical care programmes.
Conclusions
Rates for cure• The effectiveness of tuberculosis (TB) control programmes depends critically on patients completing 
appropriate treatment. 
• This study aimed to outline the cure and discontinuation 
rates of patients enrolled in the Pernambuco 
Tuberculosis Control Programme (PECT), based on 
dispensing data.
• Study was conducted in three sites in Recife, state of 
Pernambuco, Brazil.
• Data were collected between 07-11/2014, through 
reports from the stock management software for 
public pharmacies (HORUS) for PECT outpatients 
(n=948; 232, 348 and 368 in sites A, B and C, 
respectively)
• “Cure”  was defined by the software as medicines 
collection for three, six or nine consecutive months 
without interruption, depending on the treatment 
scheme.
• “Discontinuation” was defined as a non-sequential 
collection of medicines or treatment interruption for 
two consecutive months or more. 
• Patients were assigned an “undetermined” status if 
treatment was ongoing.
• Qui-squared test, Fisher’s exact test and bootstrap 
analysis were performed with R statistical computing. 
• Ethical approval was granted.
Cure and discontinuation rates for PECT outpatients.
SITE	A SITE	B SITE	C
35.9 % 23.6 % 31.0 %
Rates for treatment discontinuation
SITE	A SITE	B SITE	C
3.4% 27.8 % 9.0 %
• Discontinuation rates were significantly different 
among the sites A, B and C (p< 0.05). 
• Bootstrap analysis showed that the overall the 
proportion of patients with an "undetermined" 
status in each site did not significantly change 
these differences.
8 general practice units 
+ 1 polyclinic
1 hospital for 
medium-complexity  
patients 
1 hospital for 
high-complexity 
patients 
SITE A SITE B SITE C
